Rectal administration of propylthiouracil in suppository form in patients with thyrotoxicosis and critical illness: Case report and review of literature

Endocrine Practice

Volumn 12, Issue 1, 2006, Pages 43-47

  Zweig, Susan B ^a   Schlosser, Jonathan R ^a   Thomas, Sylvia A ^a   Levy, Carol J ^b   Fleckman, Adrienne M ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROPYLTHIOURACIL;

CASE REPORT; CRITICAL ILLNESS; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; RECTAL DRUG ADMINISTRATION; REVIEW; RISK ASSESSMENT; STOMACH ULCER; SUPPOSITORY; THYROTOXICOSIS; TREATMENT OUTCOME; ULCER PERFORATION;

ADMINISTRATION, RECTAL; CRITICAL ILLNESS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PEPTIC ULCER PERFORATION; PROPYLTHIOURACIL; RISK ASSESSMENT; STOMACH ULCER; SUPPOSITORIES; THYROTOXICOSIS; TREATMENT OUTCOME;

EID: 33646855217     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.12.1.43     Document Type: Article

References (15)

1. Chiovato L, Barbesino G, Pinchera A. Graves' disease. In: DeGroot LJ, Jameson JL, Burger HG, et al, eds. Endocrinology. 4th ed. Philadelphia, PA: WB Saunders, 2001: 1422-1449.
2. Okuno A, Taguchi T, Inyaku F, Yano K, Suzuki Y. Pharmacokinetics of propylthiouracil in children and adolescents with Graves disease after a single oral dose. Pediatr Pharmacol (New York). 1983;3:43-47.
3. Ringhand HP, Ritschel WA, Meyer MC, Straughn AB, Hardt T. Pharmacokinetics of propylthiouracil upon p.o. administration in man. Int J Clin Pharmacol Ther Toxicol. 1980;18:488-493.
4. Antithyroid agents. In: Drug Information for the Health Care Professional: United States Pharmacopeia DI 2000. 20th ed. Englewood, CO: Micromedex, 2000: 461-466.
5. Winter ME. Interpretation of plasma drug concentrations. In: Koda-Kimble MA, Young LY, eds. Basic Clinical Pharmacokinetics. Vancouver, WA: Applied Therapeutics, 1993: 67-75.
6. Kampmann JP, Hansen JM. Clinical pharmacokinetics of antithyroid drugs. Clin Pharmacokinet. 1981;6:401-428.
7. Nabil N, Miner DJ, Amatruda JM. Methimazole: an alternative route of administration. J Clin Endocrinol Metab. 1982;54:180-181.
8. Bartle WR, Walker SE, Silverberg JD. Rectal absorption of propylthiouracil. Int J Clin Pharmacol Ther Toxicol. 1988;26:285-287.
9. Walter RM Jr, Bartle WR. Rectal administration of propylthiouracil in the treatment of Graves' disease. Am J Med. 1990;88:69-70.
10. Yeung SC, Go R, Balasubramanyam A. Rectal administration of iodide and propylthiouracil in the treatment of thyroid storm. Thyroid. 1995;5:403-405.
11. Cansler CL, Latham JA, Brown PM Jr, Chapman WH, Magner JA. Duodenal obstruction in thyroid storm. South Med J. 1997;90:1143-1146.
12. Jongjaroenprasert W, Akarawut W, Chantasart D, Chailurkit L, Rajatanavin R. Rectal administration of propylthiouracil in hyperthyroid patients: comparison of suspension enema and suppository form. Thyroid. 2002;12:627-631.
13. Burman KD, Wartofsky L. Iodine effects on the thyroid gland: biochemical and clinical aspects. Rev Endocr Metab Disord. 2000;1:19-25.
14. Ross DS. Thyroid storm. In: Rose BD, ed. UpToDate. Wellesley, MA, 2004.
15. Gregoire G, Aris-Jilwan N, Vinet B, Bouchereau F, Comtois R. Intravenous administration of propylthiouracil in treatment of a patient with Graves' disease. In: Program and abstracts of the 77th Annual Meeting of The Endocrine Society, June 14-17, 1995, Washington, DC. Abstract P3-464.